Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal
Global Blood Therapeutics Downgraded by RBC to Sector Perform From Outperform, Price Target Raised to $68.50 From $60 Amid Pfizer Deal
加拿大皇家银行将Global Blood Therapeutics的评级从跑赢大盘下调至板块，在辉瑞交易中，目标股价从60美元上调至68.50美元
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册